Inrozol (Itraconazole)

Itraconazole inhibits the fungal enzyme lanosterol 14α‑demethylase, a cytochrome P450 isoform required for converting lanosterol to ergosterol. By blocking this step, the drug disrupts fungal cell‑membrane synthesis, leading to accumulation of toxic sterol intermediates and inhibition of fungal growth.

The dosage of Inrozol is individualized by the prescribing clinician based on the type and severity of the fungal infection, patient weight, renal and hepatic function, and potential drug interactions. Only a qualified prescriber should determine the appropriate regimen.

Safety of itraconazole in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Inrozol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other azole antifungals, itraconazole offers a broad spectrum against many dimorphic fungi and yeasts and has a longer half‑life, allowing once‑daily dosing in many cases. However, it has a higher potential for drug‑drug interactions via CYP3A4 inhibition than some newer agents such as voriconazole.

Inrozol should be stored at temperatures below 25 °C in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability. Do not refrigerate unless specifically instructed by the manufacturer.

Inrozol is taken orally, usually with a full glass of water. The tablet should be swallowed whole and not crushed or chewed unless the prescriber advises otherwise. Food may affect absorption, so follow the prescribing information regarding administration with or without meals.

The most serious adverse effects of itraconazole include hepatotoxicity, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, and cardiac complications including heart failure or QT‑interval prolongation. Patients should be monitored for liver enzyme elevations and cardiac symptoms during therapy.

Inrozol is contraindicated in patients with known hypersensitivity to itraconazole or any azole antifungal. It should also be avoided in individuals with severe heart failure, uncontrolled arrhythmias, or those taking strong CYP3A4 inhibitors unless the prescriber determines the benefits outweigh the risks.